These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 38111052)

  • 1. Effect of denosumab on glucose metabolism in postmenopausal osteoporotic women with prediabetes: a study protocol for a 12-month multicenter, open-label, randomized controlled trial.
    Wang Y; Jiang Y; Li J; Lin X; Luo Y; Tan S; Yang H; Gao Z; Cui X; Yin P; Kong D; Gao Y; Cheng Y; Zhang L; Tang P; Lyu H
    Trials; 2023 Dec; 24(1):812. PubMed ID: 38111052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of denosumab on fasting glucose in women with diabetes or prediabetes from the FREEDOM trial.
    Napoli N; Pannacciulli N; Vittinghoff E; Crittenden D; Yun J; Wang A; Wagman R; Schwartz AV
    Diabetes Metab Res Rev; 2018 May; 34(4):e2991. PubMed ID: 29430796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Denosumab in postmenopausal women with low bone mineral density.
    McClung MR; Lewiecki EM; Cohen SB; Bolognese MA; Woodson GC; Moffett AH; Peacock M; Miller PD; Lederman SN; Chesnut CH; Lain D; Kivitz AJ; Holloway DL; Zhang C; Peterson MC; Bekker PJ;
    N Engl J Med; 2006 Feb; 354(8):821-31. PubMed ID: 16495394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of denosumab, a human monoclonal antibody of receptor activator of nuclear factor kappa-B ligand (RANKL), upon glycemic and metabolic parameters: Effect of denosumab on glycemic parameters.
    Abe I; Ochi K; Takashi Y; Yamao Y; Ohishi H; Fujii H; Minezaki M; Sugimoto K; Kudo T; Abe M; Ohnishi Y; Mukoubara S; Kobayashi K
    Medicine (Baltimore); 2019 Nov; 98(47):e18067. PubMed ID: 31764838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alendronate improves fasting plasma glucose and insulin sensitivity, and decreases insulin resistance in prediabetic osteopenic postmenopausal women: A randomized triple-blind clinical trial.
    Karimi Fard M; Aminorroaya A; Kachuei A; Salamat MR; Hadi Alijanvand M; Aminorroaya Yamini S; Karimifar M; Feizi A; Amini M
    J Diabetes Investig; 2019 May; 10(3):731-737. PubMed ID: 30267620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.
    Lewiecki EM; Miller PD; McClung MR; Cohen SB; Bolognese MA; Liu Y; Wang A; Siddhanti S; Fitzpatrick LA;
    J Bone Miner Res; 2007 Dec; 22(12):1832-41. PubMed ID: 17708711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effect of denosumab on bone microarchitecture as assessed by tissue thickness-adjusted trabecular bone score in postmenopausal women with osteoporosis: results from FREEDOM and its open-label extension.
    Hans D; McDermott M; Huang S; Kim M; Shevroja E; McClung M
    Osteoporos Int; 2023 Jun; 34(6):1075-1084. PubMed ID: 36862192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Bone HG; Bolognese MA; Yuen CK; Kendler DL; Wang H; Liu Y; San Martin J
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2149-57. PubMed ID: 18381571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.
    Kendler DL; Roux C; Benhamou CL; Brown JP; Lillestol M; Siddhanti S; Man HS; San Martin J; Bone HG
    J Bone Miner Res; 2010 Jan; 25(1):72-81. PubMed ID: 19594293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
    Leder BZ; Tsai JN; Uihlein AV; Wallace PM; Lee H; Neer RM; Burnett-Bowie SA
    Lancet; 2015 Sep; 386(9999):1147-55. PubMed ID: 26144908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial.
    Miller PD; Bolognese MA; Lewiecki EM; McClung MR; Ding B; Austin M; Liu Y; San Martin J
    Bone; 2008 Aug; 43(2):222-229. PubMed ID: 18539106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Denosumab Inhibition of RANKL and Insulin Resistance in Postmenopausal Women with Osteoporosis.
    Lasco A; Morabito N; Basile G; Atteritano M; Gaudio A; Giorgianni GM; Morini E; Faraci B; Bellone F; Catalano A
    Calcif Tissue Int; 2016 Feb; 98(2):123-8. PubMed ID: 26498169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Denosumab: a review of its use in the treatment of postmenopausal osteoporosis.
    Moen MD; Keam SJ
    Drugs Aging; 2011 Jan; 28(1):63-82. PubMed ID: 21174488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase III randomized, double-blind, placebo-controlled trial of the denosumab biosimilar QL1206 in postmenopausal Chinese women with osteoporosis and high fracture risk.
    Zhang H; Gu JM; Chao AJ; Cheng Q; Teng DH; Yu JM; Wang BW; Huo YN; Mao L; Zhang Q; Yang H; Yan SG; Zhang KQ; Zhao XL; Lin H; Pei Y; Yuan Z; Dai RC; He L; Chen L; Su YF; Deng ZL; You L; Ban B; Zhu M; Cao YL; Zhu YK; Li ZJ; Zhang Z; Yi CQ; Lu YB; Wang G; Han CC; Wang ZJ; Li XX; Zhang ZL
    Acta Pharmacol Sin; 2023 Feb; 44(2):446-453. PubMed ID: 35896694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis.
    McClung MR; Lippuner K; Brandi ML; Zanchetta JR; Bone HG; Chapurlat R; Hans D; Wang A; Zapalowski C; Libanati C
    Osteoporos Int; 2017 Oct; 28(10):2967-2973. PubMed ID: 28748386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate.
    Beck TJ; Lewiecki EM; Miller PD; Felsenberg D; Liu Y; Ding B; Libanati C
    J Clin Densitom; 2008; 11(3):351-9. PubMed ID: 18495508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women.
    Freemantle N; Satram-Hoang S; Tang ET; Kaur P; Macarios D; Siddhanti S; Borenstein J; Kendler DL;
    Osteoporos Int; 2012 Jan; 23(1):317-26. PubMed ID: 21927922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spotlight on denosumab in postmenopausal osteoporosis.
    Moen MD; Keam SJ
    BioDrugs; 2011 Aug; 25(4):261-4. PubMed ID: 21815702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of low dose denosumab on bone mineral density in postmenopausal women with osteoporosis after a transition from 60 mg dose: a prospective observational study.
    Khan AA; AbuAlrob H; M'Hiri I; Ali DS; Dandurand K; Said H; Alkassem H; Hakami Y; Hweija I; Iqbal S; Romanovschi M; Mehmood S; Zariffeh H; Guyatt G; Ibrahim Q; Brignardello-Petersen R; Syed HI
    Endocrine; 2023 Jun; 80(3):647-657. PubMed ID: 37186270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
    Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
    Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.